BackEvents

KEDI U.S. Next Tech TOP10 Index

TickerKUNTT10
BloombergKUNTT10
CurrencyUSD

Sentiment Summary

Positive
2
Neutral
5
Negative
3

Recent Events

8/10/2026, 12:00:00 AM
Oklo Inc (OKLO)
Earnings Release

Next quarterly earnings release for Q2 2026 is expected.

8/6/2026, 12:00:00 AM
Rocket Lab Corp (RKLB)
Earnings Release

Second Quarter 2026 financial results and conference call are scheduled for 2026-08-06 scheduled.

8/6/2026, 12:00:00 AM
D-Wave Quantum Inc (QBTS)
Earnings Release

Next quarterly earnings report for Q2 2026 is scheduled for August 6, 2026. Low importance is estimated as the scheduling announcement typically results in minimal price movement; scheduled.

6/29/2026, 12:00:00 AM
AeroVironment Inc (AVAV)
Earnings Release

AeroVironment is scheduled to release its Q4 2026 earnings results on June 29, 2026; analysts estimate this date and a Medium importance is estimated as earnings typically drive >5% price volatility scheduled.

6/9/2026, 12:00:00 AM
Cloudflare Inc (NET)
Other

Cloudflare is scheduled to host its 2026 Investor Day at the New York Stock Exchange on 2026-06-09; such events typically result in a ~1-2% price impact, scheduled.

6/4/2026, 12:00:00 AM
AeroVironment Inc (AVAV)
Other

Multiple law firms announced the filing of a securities class action lawsuit against AeroVironment on June 4, 2026, regarding the SCAR program; a Medium importance is estimated as legal risks often impact price by >5%.

6/2/2026, 12:00:00 AM
D-Wave Quantum Inc (QBTS)
Other

Chief Financial Officer John M. Markovich sold 2,908 shares of common stock on June 2, 2026.

6/1/2026, 12:00:00 AM
Oklo Inc (OKLO)
Other

CFO Richard Craig Bealmear and CEO Jacob Dewitte sold 73,081 and 60,000 shares, respectively, on 2026-06-01 under a pre-arranged 10b5-1 trading plan, leading to an 11% stock price decline.

6/1/2026, 12:00:00 AM
ViaSat Inc (VSAT)
Other

Viasat announced on 2026-06-01 it was selected by Lockheed Martin to provide satellite communications technology for NOAA's next-generation C-130J aircraft. This is estimated to have a >=5% impact on revenue due to the contract's scale.

5/30/2026, 12:00:00 AM
Cogent Biosciences Inc (COGT)
Other

Presentation of detailed positive data from the PEAK Phase 3 trial for bezuclastinib in GIST at the 2026 ASCO Annual Meeting on 2026-05-30, showing a median Progression-Free Survival of 16.5 months vs 9.2 months for the control arm; high impact (≥10%) expected due to pivotal trial results, scheduled.

By Event Type